A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

Clinical trial NCT06997627 · RECRUITING

Trial details

NCT number: NCT06997627
Sponsor: GC Biopharma Corp
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Tetanus-diphtheria-acellular Pertussis (Tdap)

Start date: 2025-06-05
Primary completion: 2026-05-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.